BGSF Stock (NYSE:BGSF), Trade Ideas

BGSF

BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.

Long Ideas

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

NKLA

PLOW

TORO

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.

Top 5 Industrials Stocks Which Could Blast Off In Q2

ARIS

XMTR

Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In March

Short Ideas

AJRD

PFMT

WLFC

The most overbought stocks in the industrials sector presents an opportunity to go short on these overvalued companies.

Top 5 Industrials Stocks That May Plunge

BGSF Inc

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Overweight and maintains $45 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target

On Wednesday,&nbsp;Boston Scientific Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/boston-scientific-recalls-obsidio-conformable-embolic-increased-bowel-ischemia-risk-when-used-lower" rel="noreferrer noopener">said</a>&nbsp;it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall.
An investigation determined that delivery of Obsidio Embolic using the aliquot technique, a commonly used delivery method in embolization procedures, for lower gastrointestinal (GI) bleeding embolization, implies a high risk of bowel ischemia.
The most serious and the most common adverse health consequence is the need to perform major surgery such as bowel resection and/or diverting colostomy.&nbsp;
Use of this product with the aliquot technique may prevent blood and oxygen flow to organs, including the small bowel (ischemia) or non-target embolization, all of which may lead to prolonged hospitalization, the need for additional surgery, or death.
Eleven incidents were reported, seven injuries, and two deaths related to this issue.
The FDA said that recall is a correction, not a product removal.
On February 21, Boston Scientific issued an advisory notice explaining that the aliquot technique is not recommended with Obsidio Embolic when used for procedures treating lower GI bleeding.
The Obsidio Conformable Embolic (Obsidio Embolic) is a premixed embolic agent delivered minimally invasively to block (occlude) blood flow to specific blood vessels.&nbsp;
After injection, Obsidio Embolic creates a solid cast in the vessel and halts blood flow. It is intended for single use to embolize hypervascular tumors and to occlude blood flow in peripheral blood vessels that are bleeding and/or hemorrhaging.
The company has issued a recall for around 1,600 devices distributed between May 8, 2023, and February 8, 2024.
In January, Boston Scientific&nbsp;agreed to acquire&nbsp;Axonics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXNX#NASDAQ">AXNX</a>) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value of&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36534875/why-is-bladder-disorder-focused-axonics-stock-trading-higher-today" rel="noreferrer noopener">roughly $3.7 billion</a>.
The Axonics product portfolio includes the Axonics R20 and the Axonics F15 Systems used to deliver sacral neuromodulation therapy, a minimally invasive procedure for overactive bladder and fecal incontinence.&nbsp;
Price Action:&nbsp;BSX shares are down 0.32% at $67.71 on the last check Thursday.

Biotech

Large Cap

Health Care

General

AXNX

FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $463.0, along with a high estimate of $522.00 and a low estimate of $402.00. This upward trend is apparent, with the current average reflecting a 5.05% increase from the previous average price target of $440.75.
<img src="https://www.benzinga.com/files/images/story/2024/1713448883_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of argenx among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$521.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>$451.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$471.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$402.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$471.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$490.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$478.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Allison Bratzel</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$522.00</td>
<td>$518.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to argenx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of argenx compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for argenx's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of argenx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on argenx analyst ratings.</a>
<h2>Delving into argenx's Background</h2>
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
<h3>Unraveling the Financial Story of argenx</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: argenx's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 133.6%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: argenx's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -24.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): argenx's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.42%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): argenx's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.18%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.0, argenx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARGX

The Analyst Verdict: argenx In The Eyes Of 12 Experts

Analysts' ratings for Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.6, a high estimate of $73.00, and a low estimate of $48.00. This current average reflects an increase of 3.27% from the previous average price target of $60.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1713448861_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Johnson Controls Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Puneet Garg</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$60.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Johnson Controls Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson Controls Intl compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Johnson Controls Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Johnson Controls Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson Controls Intl analyst ratings.</a>
<h2>Discovering Johnson Controls Intl: A Closer Look</h2>
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.
<h3>Breaking Down Johnson Controls Intl's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Johnson Controls Intl's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 0.43%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 6.14%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Johnson Controls Intl's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Johnson Controls Intl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.85%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Johnson Controls Intl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.64.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Johnson Controls Intl: Insights From 10 Financial Analysts

In the preceding three months, 6 analysts have released ratings for Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.33, along with a high estimate of $39.00 and a low estimate of $35.00. This upward trend is evident, with the current average reflecting a 7.27% increase from the previous average price target of $34.80.
<img src="https://www.benzinga.com/files/images/story/2024/1713448849_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Citizens Financial Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ken Usdin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Citizens Financial Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Citizens Financial Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Citizens Financial Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Citizens Financial Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CFG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Citizens Financial Group analyst ratings.</a>
<h2>Discovering Citizens Financial Group: A Closer Look</h2>
Citizens Financial Group is a bank holding company headquartered in Providence, Rhode Island. Its two primary business segments are consumer banking and commercial banking. Citizens offers a mix of retail and commercial products including capital markets and wealth options. The bank has over 1,100 branches in 14 states, although it is concentrated in the Northeast. It has over $220 billion of total assets. It generates maximum revenue from Consumer Banking Segment.
<h3>Citizens Financial Group: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Citizens Financial Group's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -12.11%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Citizens Financial Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.0%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Citizens Financial Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.74%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Citizens Financial Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.07%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Citizens Financial Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.63, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Citizens Financial Group Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $165.8, along with a high estimate of $200.00 and a low estimate of $136.00. This current average has increased by 11.28% from the previous average price target of $149.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1713448840_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Chart Industries among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Ian Macpherson</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$151.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$136.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chart Industries. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Chart Industries's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Chart Industries's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chart Industries analyst ratings.</a>
<h2>Unveiling the Story Behind Chart Industries</h2>
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas (LNG) industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
<h3>Chart Industries: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Chart Industries's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 129.95%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Chart Industries's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chart Industries's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.59%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Chart Industries's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.4, Chart Industries faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLS

Chart Industries Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) has outperformed the market over the past 5 years by 6.15% on an annualized basis producing an average annual return of 17.45%. Currently, Hess has a market capitalization of $46.45 billion. 
Buying $1000 In HES: If an investor had bought $1000 of HES stock 5 years ago, it would be worth $2,221.13 today based on a price of $150.77 for HES at the time of writing.
<h3>Hess's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713448832_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

In the preceding three months, 6 analysts have released ratings for Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.33, a high estimate of $205.00, and a low estimate of $152.00. Surpassing the previous average price target of $170.50, the current average has increased by 3.42%.
<img src="https://www.benzinga.com/files/images/story/2024/1713448828_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Hess by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$156.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hess. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hess compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hess's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hess's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HES/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hess analyst ratings.</a>
<h2>Get to Know Hess Better</h2>
Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.
<h3>Hess's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Hess's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.62% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Hess's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.72%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.07, Hess faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Hess: What You Need To Know

Pioneer Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PXD#NYSE">PXD</a>) has outperformed the market over the past 15 years by 5.55% on an annualized basis producing an average annual return of 17.94%. Currently, Pioneer Natural Resources has a market capitalization of $62.52 billion. 
Buying $1000 In PXD: If an investor had bought $1000 of PXD stock 15 years ago, it would be worth $12,407.74 today based on a price of $267.62 for PXD at the time of writing.
<h3>Pioneer Natural Resources's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713448826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $12,000 Today

Macro Economic Events

Econ #s

Economics

USA Existing Home Sales (MoM) For March -4.3% Vs 9.5% Prior

In the last three months, 4 analysts have published ratings on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dentsply Sirona, revealing an average target of $41.5, a high estimate of $42.00, and a low estimate of $41.00. Surpassing the previous average price target of $41.00, the current average has increased by 1.22%.
<img src="https://www.benzinga.com/files/images/story/2024/1713448817_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Dentsply Sirona's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Dentsply Sirona's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dentsply Sirona's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>All You Need to Know About Dentsply Sirona</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Dentsply Sirona: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Dentsply Sirona's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 2.95%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dentsply Sirona's net margin is impressive, surpassing industry averages. With a net margin of 6.62%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dentsply Sirona's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.01%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Dentsply Sirona's ROA stands out, surpassing industry averages. With an impressive ROA of 0.92%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.7, Dentsply Sirona adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XRAY

A Glimpse Into The Expert Outlook On Dentsply Sirona Through 4 Analysts

USA Existing Home Sales For March 4.19M Vs 4.20M Est; 4.38M Prior

US Leading Index (MoM) For March -0.3% Vs -0.1% Est.; 0.2% Prior

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Overweight and maintains $160 price target.

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Elevance Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) reported first-quarter revenues of $42.3 billion, up 0.9% year over year, marginally missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $42.6 billion</a>.&nbsp;
Higher premium yields drove this increase to reflect medical cost trends and growth in Carelon, including a full quarter of revenue from BioPlus, partially offset by attrition&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38308922/elevance-health-reports-first-quarter-2024-results" rel="noreferrer noopener">in Medicaid membership</a>.
&#8220;First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry,&#8221; CEO Gail Boudreaux said. &#8220;We are making significant progress expanding Carelon&#8217;s capabilities, scaling our flywheel for enterprise growth, and delivering results for all stakeholders.&#8221;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37984877/insurance-coverage-for-weight-loss-drugs-elevance-cvs-health-become-first-to-extend-coverage-to-n" rel="noreferrer noopener">Elevance, CVS Health Are First Medicare Insurers To Cover Novo Nordisk&#8217;s Weight Loss Sensation Wegovy</a>.
Elevance Health&#8217;s first-quarter profit grew 12.2% year over year to $2.2 billion. The insurer reported adjusted EPS of $10.64, up 12.5% year over year and beating the consensus of $10.53.
The benefit expense ratio was 85.6 percent, an improvement of 20 basis points, driven primarily by premium rate adjustments to cover medical cost trend in Health Benefits business.
The company reported $37.3 billion in operating revenue at its health benefits arm, flat Y/Y. Elevance Health said premium increases were offset by decreases in Medicaid membership caused by the redetermination process and changes to its geographic footprint.
Elevance Health plans had about 46.2 million members, a decrease of 1.9 million or 4% year over year, driven by Medicaid. However, the company said growth in commercial and Affordable Care Act exchange enrollment helped offset some of the decreases in Medicaid.
Medicaid enrollment was&nbsp;<a target="_blank" href="https://www.elevancehealth.com/content/dam/elevance-health/documents/earnings/1Q2024_ELV_Earnings_Release.pdf" rel="noreferrer noopener">down</a>&nbsp;21.5% to 9.3 million.
Carelon&#8217;s operating revenue reached $12.1 billion, up 5% backed by expansion within CarelonRx, the company&#8217;s pharmacy benefit manager, and new risk-based capabilities within Carelon Services.
Guidance:&nbsp;Elevance boosted its guidance for 2024 to over $37.20 in earnings per share compared to the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36762117/health-insurer-elevances-q4-earnings-dividend-increase-drop-in-medicaid-enrollment-upbeat-2024-outl" rel="noreferrer noopener">prior outlook of over $37.10</a>&nbsp;and the consensus of $37.15.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37827161/kroger-passes-the-baton-sells-specialty-pharmacy-division-to-carelonrx" rel="noreferrer noopener">Kroger Passes The Baton: Sells Specialty Pharmacy Division To CarelonRx</a>.
Price Action: ELV shares are up 4.44% at $531.59 during the premarket session on the last check Thursday.
Photo Vlad Deep for Unsplash

Earnings

Guidance

Movers

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Elevance Health Clocks $2.2B Q1 Net Profit Despite 21% Drop In Medicaid Enrollment, Lifts Annual Guidance

By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_18042024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex</a> Analytical Department
The British pound sterling is showing signs of recovery, bouncing back from a five-month low, with GBP/USD stabilising around the 1.2470 mark on Thursday. This rebound is attributed to the release of UK inflation data, suggesting a possible monetary policy easing by the Bank of England (BoE).
The UK&#39;s consumer price index (CPI) slowed to 3.2% year-on-year in March, down from 3.4% in February, marking the lowest inflation rate in two and a half years. This slowdown has raised investor optimism regarding potential policy easing by the BoE, particularly since core inflation has also dropped to its lowest since mid-2021. However, persistent inflation in the services sector may lead to cautious deliberation among certain members of the monetary committee.
Meanwhile, representatives from the US Federal Reserve have reiterated that US interest rates are likely to remain high for an extended period. In contrast, the BoE is perceived as relatively stable, potentially initiating monetary policy easing by summer.
The first quarter saw significant pressures from the tight employment market and shocks from rising energy prices, which initially suggested that the BoE might follow the European Central Bank (ECB) and the Fed in lowering interest rates. However, market conditions have shifted considerably. Exchange analysts now anticipate that the ECB might cut interest rates by June, the BoE by September, and the Fed only in Q4.
Technical analysis of GBP/USD
<a href="https://www.benzinga.com/files/u117641/gbpusdh4_7.png"><img alt="" src="https://www.benzinga.com/files/u117641/gbpusdh4_7.png" style="height:716px; width:1596px" /></a>
The H4 chart for GBP/USD indicates that after forming a consolidation range of around 1.2547, the pair has reached the target of 1.2450 with a downward exit. A new consolidation range is currently forming above this level. A break below this range may drive prices lower to 1.2380, with a subsequent correction to retest 1.2547 (testing from below) before a possible continuation to 1.2200. This bearish scenario is supported by the MACD oscillator, whose signal line is below zero and is trending downwards.
<a href="https://www.benzinga.com/files/u117641/gbpusdh1_7.png"><img alt="" src="https://www.benzinga.com/files/u117641/gbpusdh1_7.png" style="height:716px; width:1596px" /></a>
On the H1 chart, the GBP/USD has completed a decline to 1.2406 and is currently undergoing a correction to 1.2491. Following this correction, a new decline to 1.2381 is anticipated. The Stochastic oscillator, currently above 80, is poised for a sharp decline to the 20 mark, reinforcing the likelihood of further downward movement in the short term.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

British Pound Shows Signs Of Recovery Amid Favourable Inflation Data

Cantor Fitzgerald analyst Louise Chen reiterates Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Overweight and maintains $135 price target.

Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price Target

Iridium Communications Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">&nbsp;trading higher on Thursday.</a>
The company reported first-quarter earnings per share of 16 cents, outpacing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38310226/iridium-announces-first-quarter-2024-results" rel="noreferrer noopener">Wallstreet estimate of 15 cents</a>. Quarterly revenues of $203.85 million&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the analyst consensus of $193.75 million</a>, driven by strong service revenue growth and subscriber expansion.
Total billable subscribers grew 14% year-over-year to 2.33 million, led by growth in commercial IoT.
Operational EBITDA for the first quarter was $115.0 million, as compared to $111.9 million for the prior-year period, representing a year-over-year increase of 3%.&nbsp;
Net income benefitted from a year-over-year decrease in depreciation expense and continued growth in total commercial services revenue.
Quarterly sales consisted of $148.6 million of service revenue and $55.3 million of revenue related to equipment sales and engineering and support projects.
&#8220;Continued strong service revenue growth fueled Iridium&#8217;s business results in the first quarter,&#8221; said Matt Desch, CEO, Iridium.&nbsp;
Desch added, &#8220;Subscriber growth and demand for Iridium&#8217;s mission-critical applications are driving new service development and free cash flow.&#8221;
What&#8217;s Next?
Iridium Communications&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n37153759/iridium-announces-2023-results-company-issues-2024-outlook" rel="noreferrer noopener">reiterated</a>&nbsp;total service revenue growth between 4% and 6% for full-year 2024. Total service revenue&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">for 2023 was $584.5 million.</a>
Full-year 2024 OEBITDA is reaffirmed between $460 million and $470 million. OEBITDA for 2023 was $463.1 million.
The company now expects longer-term cash tax rate will move closer to the statutory rate in 2028.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, IRDM stock has lost over 53% in the past year. Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and&nbsp;ARK Autonomous Technology &amp; Robotics ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>).
Read Next:<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38238454/vingroups-vinfast-faces-financial-risks-amidst-global-ambitions-with-5-7b-loss-over-past-three-y" rel="noreferrer noopener">&nbsp;Vingroup&#8217;s VinFast Faces Financial Risks Amidst Global Ambitions, With $5.7B Loss Over Past Three Years</a>
Price Action: IRDM shares are trading higher by 10.7% to $27.37 on the last check Thursday. 
Photo via Shutterstock

Equities

ARKQ

ARKX

IRDM

Iridium Communications Jump 10% After Q1 Results - Here's Why

Contracts

Diana Shipping Announces Time Charter Contract With Bohai Shipping For m/v P. S. Palios; Gross Charter Rate Is $27,150/Day Minus 5% Commission Paid To Third Parties For Period Until Minimum Nov. 1, 2025 Up To Maximum Dec. 31, 2025

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and maintains $815 price target.

Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $815 Price Target

BGSF: Dividend Yield Of 6.3% And A Strong Balance Sheet

BG Staffing declares $0.15 dividend

Warning: BGSF is at high risk of performing badly

Notable earnings after Wednesday's close

BG Staffing Q4 2023 Earnings Preview

BG Staffing Non-GAAP EPS of $0.21 beats by $0.10, revenue of $73.6M misses by $1.76M

BGSF, Inc. (BGSF) Q4 2023 Earnings Call Transcript

BGSF Inc (BGSF) reported better than expected earnings this afternoon for Q4 2023. Analyst expectations for Bgsf Inc earnings per share (EPS) were at $0.08, with the company surpassing those estimates with a reported EPS of $0.21, leading to a positive surprise of $0.13 per share (163%). Bgsf Inc's earnings rose 11% year-o

Bgsf Inc Up 1.14% To $9.76 After Earnings Beat

ANIK

BOXL

CHRS

ECOR

FOSL

FTCI

GORO

GRWG

HEAR

HNRG

JUSHF

LRFC

NVGS

OPTT

PANL

PATH

PFIE

PLNH

PTMN

SCPH

SPRO

SSSS

Press Releases

BGSF, Inc. Presenting at the 14th Annual Midwest IDEAS Investor Conference on August 23rd in Chicago, IL

BGSF, Inc. Announces Timing of Third Quarter Fiscal 2023 Results and Earnings Conference Call

BGSF, Inc. Reports Third Quarter 2023 Financial Results

BGSF, Inc. Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 15th in Dallas, TX

BGSF, Inc. Announces 37th Consecutive Quarterly Dividend

BGSF Named a Workday Partner

BGSF, Inc. Announces Timing of Fourth Quarter and Fiscal Year 2023 Results and Earnings Conference Call

BGSF's Beth Garvey Recognized as an Influential Leader in Staffing Industry Analysts (SIA) 2024 Staffing 100 North America List